http://web.archive.org/web/20140906212015id_/http://www.dailymail.co.uk/news/article-2630908/Takeover-set-years-warn-AstraZeneca-scientists-call-board-fight-companys-independence.html

years of scientific work could be undone at @entity3 if a deal goes ahead with @entity5 , experts at the firm have warned			1
any takeover would be ‘ disruptive ’ for its pipeline of new drugs , they said , calling on the board to ‘ fight ’ for the company ’s independence			1
the comments are in contrast to those of chief executive @entity15 , who stands to make up to £ 31.5million if the deal goes ahead			1
expert : concerns have been raised by dr @entity19 ( pictured ) , @entity3 's executive vice chairman for innovative medicines and early development he has refused to rule out a deal on the grounds that the interests of shareholders must be taken into account			1
concerns have been raised by dr @entity19 , @entity3 ’s executive vice chairman for innovative medicines and early development			2
he said the firm had spent years developing trust in an industry that relies on close collaboration between scientists in a variety of fields and organisations			2
‘ it ’s quite fragile because it ’s all dependent on people , ’ he said			0
‘ if you destabilise that , it could have a hugely detrimental impact on science in the @entity44			0
’ the company was confident it could keep delivering lucrative drugs and other treatments without outside intervention , he added			0
describing its ethos as ‘ innovative and collaborative ’ , he said : ‘ that is our culture			0
that is what i am fighting to retain			0
’ dr @entity55 , head of discovery science , warned a merger could lead to job losses or the closure of facilities			0
and dr @entity61 , vice president of @entity62 , the firm ’s biologics arm , insisted ‘ continuity is crucial ’ for the long - term commitments vital to life sciences , where a single discovery can take decades of research			0
‘ big mergers are disruptive			0
that ’s an important point to put , ’ she said			0
the merger between @entity5 and @entity3 would be the largest in @entity44 corporate history creating a £ 63billion business			1
takeover : the comments are in contrast to those of @entity3 's chief executive @entity15 ( pictured ) , who stands to make up to £ 31.5million if the deal goes ahead the @entity82 firm has sought to calm fears about the impact on the pharmaceutical industry in the @entity44 with pledges about its commitment			1
but it has admitted there could be job losses through ‘ financial synergies ’			0
mr @entity15 has 152,000 shares in his firm , worth £ 8.3million			1
another 421,000 shares in a long - term incentive scheme would increase the total to £ 31.5million			1
together with shares held by senior directors , the board ’s windfall would reach £ 60million.in an interview with the @entity102 on thursday mr @entity15 insisted a deal was ‘ not inevitable ’			1
he said yesterday : ‘ we have complete confidence in our strategy as an independent company and remain focused on delivering new medicines for patients			0
’ meanwhile , it has emerged that @entity5 executives cashed in shares worth millions of pounds shortly before offering a higher bid for @entity3			2
chief executive @entity114 sold £ 6.3million of his holdings on february 26			1
other senior figures to sell stakes in the days that followed included finance chief @entity119 , who made £ 5.3million , and principal accounting officer @entity120 , who netted £ 1.8million			1
@entity5 ’s share value has fallen nine per cent since mr @entity114 released his stake			2
the company announced a takeover bid in january and made a revised offer on april 28 of £ 48 a share , valuing the firm at around £ 63billion			1
mr @entity15 said the offer ‘ seriously undervalues ’ the company			2
city analysts believe @entity5 will offer £ 53 to £ 55 - a - share			2
@entity3 ’s shares rose more than 2 per cent yesterday , gaining 97p to close at 4,823.5p on the @entity131 , as investors bet on a higher bid .			0

scientists say takeover by @entity5 would be ' disruptive ' to their work
comments are in contrast to those made by company 's chief executive
@entity15 stands to make up to £ 31.5million if the deal goes ahead

@entity3:AstraZeneca
@entity15:Pascal Soriot
@entity5:Pfizer
@entity62:MedImmune
@entity82:US
@entity19:Mene Pangalos
@entity44:UK
@entity102:Daily Mail
@entity114:Read
@entity119:Frank D’Amelio
@entity55:Mike Snowden
@entity131:London Stock Exchange
@entity120:Loretta Cangialosi
@entity61:Jane Osbourn